Security Survey Notes Data Threats


By Salvatore Salamone Bio-IT World

This month, the FBI and the Computer Security Institute (CSI) released the results of their most recent annual Computer Crime and Security Survey. And some of the findings should cause life science companies to re-examine their security procedures, software, and systems to make sure new threats are not hazardous to their organization's well being.

For instance, 47 percent of the 616 respondents said their organization had experienced laptop thefts within the last 12 months. This phenomenon is on the rise. For example, an April article in the San Francisco Chronicle noted that the number of laptops stolen in the city had nearly tripled from 2004 to last year and that thieves increasingly are staking out coffee shops to steal laptops when customers were distracted or stepped away from their table.

Naturally, the consequences of a stolen laptop vary greatly depending on the data stored on it. If clinical trial data containing patient information is on a stolen laptop, that represents HIPAA compliance problems. And if a researcher's laptop is stolen, that could result in the loss of intellectual property.

Even if data is stored safely within an organization, it's still not safe. The survey found that 32 percent of respondents said there was unauthorized access of data within their organization. Again, there are potential intellectual property loss and HIPAA compliance implications with such security breaches.

While there is no single (or simple) solution to safeguard all data, there is increased discussion by security industry experts that data on laptops and important company data on internal storage systems should be encrypted.

This might explain EMC's announcement in late June of an agreement to acquire encryption pioneer RSA Security for just under $2.1 billion.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.